Collection 2 (Sep 2021 - Aug 2022) Articles

Articles
Shining a Light on Plaque Vulnerability and Treatment
Stone GW, Narula J
Journal:
JACC Cardiovasc Imaging

First published: June 15, 2022 DOI: 10.1016/j.jcmg.2022.04.019
View
- Share
Articles
NLA scientific statement on statin intolerance: a new definition and key considerations for ASCVD risk reduction in the statin intolerant patient
Cheeley MK, Saseen JJ, Agarwala A, et al.
Journal:
J Clin Lipidol

First published: June 9, 2022 DOI: 10.1016/j.jacl.2022.05.068
View
- Share
Articles
Time-averaged low-density lipoprotein cholesterol lowering with evolocumab: Pooled analysis of phase 2 trials
Schludi B, Giugliano RP, Sabatine MS, et al.
Journal:
J Clin Lipidol

First published: June 6, 2022 DOI: 10.1016/j.jacl.2022.05.069
View
- Share
Articles
Benefits of icosapent ethyl for enhancing residual cardiovascular risk reduction: A review of key findings from REDUCE-IT
Gaba P, Bhatt DL, Mason RP, et al.
Journal:
J Clin Lipidol

First published: June 4, 2022 DOI: 10.1016/j.jacl.2022.05.067
View
- Share
Articles
Association between REDUCE-IT criteria, coronary artery disease severity and cardiovascular events: The Western Denmark Heart Registry
Mortensen MB, Dzaye O, Razavi AC, et al.
Journal:
Eur J Prev Cardiol

First published: June 3, 2022 DOI: 10.1093/eurjpc/zwac104
View
- Share
Articles
Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease
Jones WS, Mulder H, Wruck LM, et al.
Journal:
N Engl J Med

First published: May 27, 2022 DOI: 10.1056/NEJMoa2102137
View
- Share
Articles
Lipoprotein(a) and the Risk for Coronary Heart Disease and Ischemic Stroke Events Among Black and White Adults With Cardiovascular Disease
Colantonio LD, Bittner V, Safford MM, et al.
Journal:
J Am Heart Assoc

First published: May 27, 2022 DOI: 10.1161/JAHA.121.025397
View
- Share
Articles
Alirocumab and Cardiovascular Outcomes in Patients with Previous Myocardial Infarction: Prespecified Sub-analysis from ODYSSEY OUTCOMES
Chiang CE, Schwartz GG, Elbez Y, et al.
Journal:
Can J Cardiol

First published: May 26, 2022 DOI: 10.1016/j.cjca.2022.05.021
View
- Share
Articles
Effect of Lifestyle Coaching or Enhanced Pharmacotherapy on Blood Pressure Control Among Black Adults With Persistent Uncontrolled Hypertension: A Cluster Randomized Clinical Trial
Nguyen-Huynh MN, Young JD, Ovbiagele B, et al.
Journal:
JAMA Netw Open

First published: May 18, 2022 DOI: 10.1001/jamanetworkopen.2022.12397
View
- Share
Articles
Lipoprotein(a) and its Significance in Cardiovascular Disease: A Review
Duarte Lau F, Giugliano RP
Journal:
JAMA Cardiol

First published: May 18, 2022 DOI: 10.1001/jamacardio.2022.0987
View
- Share
Articles
Effectiveness and Safety of Lipid-Lowering Drug Treatments in Japanese Patients with Familial Hypercholesterolemia: Familial Hypercholesterolemia Expert Forum (FAME) Study
Yamashita S, Masuda D, Harada-Shiba M, et al.
Journal:
J Atheroscler Thromb

First published: May 13, 2022 DOI: 10.5551/jat.62764
View
- Share
Articles
Coronary Atherosclerosis in an Asymptomatic U.S. Population: Miami Heart Study at Baptist Health South Florida
Khurram Nasir, Miguel Cainzos-Achirica, Javier Valero-Elizondo, et al.
Journal:
JACC: Cardiovascular Imaging

First published: May 11, 2022 DOI: 10.1016/j.jcmg.2022.03.010
View
- Share

1 2 3 4 5 6 … 14

Collection 2 (Sep 2021 - Aug 2022) Articles

Articles

Shining a Light on Plaque Vulnerability and Treatment

Stone GW, Narula J

Articles

NLA scientific statement on statin intolerance: a new definition and key considerations for ASCVD risk reduction in the statin intolerant patient

Cheeley MK, Saseen JJ, Agarwala A, et al.

Articles

Time-averaged low-density lipoprotein cholesterol lowering with evolocumab: Pooled analysis of phase 2 trials

Schludi B, Giugliano RP, Sabatine MS, et al.

Articles

Benefits of icosapent ethyl for enhancing residual cardiovascular risk reduction: A review of key findings from REDUCE-IT

Gaba P, Bhatt DL, Mason RP, et al.

Articles

Association between REDUCE-IT criteria, coronary artery disease severity and cardiovascular events: The Western Denmark Heart Registry

Mortensen MB, Dzaye O, Razavi AC, et al.

Articles

Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease

Jones WS, Mulder H, Wruck LM, et al.

Articles

Lipoprotein(a) and the Risk for Coronary Heart Disease and Ischemic Stroke Events Among Black and White Adults With Cardiovascular Disease

Colantonio LD, Bittner V, Safford MM, et al.

Articles

Alirocumab and Cardiovascular Outcomes in Patients with Previous Myocardial Infarction: Prespecified Sub-analysis from ODYSSEY OUTCOMES

Chiang CE, Schwartz GG, Elbez Y, et al.

Articles

Effect of Lifestyle Coaching or Enhanced Pharmacotherapy on Blood Pressure Control Among Black Adults With Persistent Uncontrolled Hypertension: A Cluster Randomized Clinical Trial

Nguyen-Huynh MN, Young JD, Ovbiagele B, et al.

Articles

Lipoprotein(a) and its Significance in Cardiovascular Disease: A Review

Duarte Lau F, Giugliano RP

Articles

Effectiveness and Safety of Lipid-Lowering Drug Treatments in Japanese Patients with Familial Hypercholesterolemia: Familial Hypercholesterolemia Expert Forum (FAME) Study

Yamashita S, Masuda D, Harada-Shiba M, et al.

Articles

Coronary Atherosclerosis in an Asymptomatic U.S. Population: Miami Heart Study at Baptist Health South Florida

Khurram Nasir, Miguel Cainzos-Achirica, Javier Valero-Elizondo, et al.

Articles

Shining a Light on Plaque Vulnerability and Treatment

Stone GW, Narula J

Share

Articles

NLA scientific statement on statin intolerance: a new definition and key considerations for ASCVD risk reduction in the statin intolerant patient

Cheeley MK, Saseen JJ, Agarwala A, et al.

Share

Articles

Time-averaged low-density lipoprotein cholesterol lowering with evolocumab: Pooled analysis of phase 2 trials

Schludi B, Giugliano RP, Sabatine MS, et al.

Share

Articles

Benefits of icosapent ethyl for enhancing residual cardiovascular risk reduction: A review of key findings from REDUCE-IT

Gaba P, Bhatt DL, Mason RP, et al.

Share

Articles

Association between REDUCE-IT criteria, coronary artery disease severity and cardiovascular events: The Western Denmark Heart Registry

Mortensen MB, Dzaye O, Razavi AC, et al.

Share

Articles

Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease

Jones WS, Mulder H, Wruck LM, et al.

Share

Articles

Lipoprotein(a) and the Risk for Coronary Heart Disease and Ischemic Stroke Events Among Black and White Adults With Cardiovascular Disease

Colantonio LD, Bittner V, Safford MM, et al.

Share

Articles

Alirocumab and Cardiovascular Outcomes in Patients with Previous Myocardial Infarction: Prespecified Sub-analysis from ODYSSEY OUTCOMES

Chiang CE, Schwartz GG, Elbez Y, et al.

Share

Articles

Effect of Lifestyle Coaching or Enhanced Pharmacotherapy on Blood Pressure Control Among Black Adults With Persistent Uncontrolled Hypertension: A Cluster Randomized Clinical Trial

Nguyen-Huynh MN, Young JD, Ovbiagele B, et al.

Share

Articles

Lipoprotein(a) and its Significance in Cardiovascular Disease: A Review

Duarte Lau F, Giugliano RP

Share

Articles

Effectiveness and Safety of Lipid-Lowering Drug Treatments in Japanese Patients with Familial Hypercholesterolemia: Familial Hypercholesterolemia Expert Forum (FAME) Study

Yamashita S, Masuda D, Harada-Shiba M, et al.

Share

Articles

Coronary Atherosclerosis in an Asymptomatic U.S. Population: Miami Heart Study at Baptist Health South Florida

Khurram Nasir, Miguel Cainzos-Achirica, Javier Valero-Elizondo, et al.

Share